Vivesto’s pipeline of development programs includes Cantrixil, in clinical development for late-stage ovarian cancer, and Docetaxel micellar, in development for advanced prostate cancer.
1Indication and product name may differ between regions.
| Product | Indication | Pre-clinical | Phase I | Phase II | Phase III | Registration/ approval | Commercial Launch | Geography |
| Cantrixil | Ovarian cancer | Global | ||||||
| Docetaxel micellar | Prostate cancer | EU/EEA | ||||||